References
- Hinshaw K, El-Refaey H, Rispin R, Templeton A. Mid-trimester termination for fetal abnormality: Advantages of a new regimen using mifepristone and misoprostol. BJOG 1995; 102: 559–560
- Lalitkumar S, Bygdeman M, Gemzell-Danielsson K. Mid-trimester induced abortion: A review. Hum Reprod Update 2007; 13: 37–52
- Induction of labour. Evidence-based Guidelines No. 9. Royal College of Obstetricians and Gynaecologists, London 2001
- Dickinson J E, Evans S F. A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality. Obstet Gynecol 2003; 101: 1294–1299
- Ulreich S, Gruslin A, Nodell C G, Pretorius D H. Fetal hydrops and ascites. Diagnostic imaging of fetal anomalies, D A Nyberg, J P McGahan, D H Pretorius, G Pilu. Lippincott Williams & Wilkins, Philadelphia 2003; 713–744
- Dodd J, O'Brien L, Coffey J. Misoprostol for second and third trimester termination of pregnancy: A review of practice at the Women's and Children's Hospital, Adelaide, Australia. Aust N Z J Obstet Gynaecol 2005; 45: 25–29
- Verhulsdonk M T, Papatsonis D N, Heydanus R. Results of pregnancy termination for foetal congenital or chromosomal disorders or intrauterine foetal death by oral mifepristone and/or intravaginal misoprostol: Results of a retrospective study. [Article in Dutch] Ned Tijdschr Geneeskd 2007; 151: 815–820
- Dickinson J E, Godfrey M E, Evans S F. Efficacy of intra-vaginal misoprostol in second-trimester pregnancy termination: A randomised controlled trial. J Matern Fetal Med 1998; 7: 115–119
- Dickinson J E, Evans S F. The optimisation of intra-vaginal misoprostol dosing schedules in second-trimester pregnancy termination. Am J Obstet Gynecol 2002; 186: 470–474
- Wilson R D, Chitayat D, McGillivray B C. Fetal ultrasound abnormalities: Correlation with fetal karyotype, autopsy findings, and postnatal outcome—five-year prospective study. Am J Med Genet 1992; 44: 586–590
- Vaknin Z, Ben-Ami I, Reish O, Herman A, Maymon R. Fetal abnormalities leading to termination of singleton pregnancy: The 7-year experience of a single medical centre. Prenat Diagn 2006; 26: 938–943
- Liao C, Wei J, Li Q, Li J, Li L, Li D. Nonimmune hydrops diagnosed during the second half of pregnancy in southern China. Fetal Diagn Ther 2007; 22: 302–305
- Wong K S, Ngai C S, Wong A Y, Tang L C, Ho P C. Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy. A randomised trial 1998; 59: 207–210, Contraception
- Wong K S, Ngai C S, Yeo E L, Tang L C, Ho P C. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: A randomised comparative trial. Hum Reprod 2000; 15: 709–712
- Tang O S, Thong K J, Baird D T. Second trimester medical abortion with mifepristone and gemeprost: A review of 956 cases. Contraception 2001; 64: 29–32
- Tang O S, Lau W N, Chan C C, Ho P C. A prospective randomized comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. Br J Obstet Gynaecol 2004; 111: 1001–1005
- Tang O S, Chan C CW, Kan A SY, Ho P C. A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12–20 weeks gestation. Hum Reprod 2005; 20: 3062–3066
- Hamoda H, Ashok P W, Flett G M, Templeton A. A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13–20 weeks gestation. Hum Reprod 2005; 20: 2348–54
- Goh S E, Thong K J. Induction of second trimester abortion (12–20 weeks) with mifepristone and misoprostol: A review of 386 consecutive cases. Contraception 2006; 73: 516–519
- Sedan O, Golan A, Girtler O, Lurie S, Debby A, Sagiv R, Evron S, Glezerman M. Role of sonography in the diagnosis of retained product of conception. J Ultrasound Med 2004; 23: 371–374